Page 22«..10..21222324..30..»

Archive for the ‘Cell Therapy’ Category

Potential of differentiated iPS cells in cell therapy without immune rejection

Jan. 25, 2013 A new study from Boston University School of Medicine (BUSM) shows that tissues derived from induced pluripotent stem (iPS) cells in an experimental model were not rejected when transplanted back into genetically identical recipients. The study, published online in Cell Stem Cell, demonstrates the potential of utilizing iPS cells to develop cell types that could offer treatment for a wide range of conditions, including diabetes, liver and lung diseases, without the barrier of immune rejection.

Ashleigh Boyd, DPhil, and Neil Rodrigues, DPhil, the study's senior authors, are assistant professors of dermatology at BUSM and researchers at the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC). They also are lead investigators at the National Institutes of Health's Center of Biomedical Research Excellence (COBRE) at Roger Williams Medical Center, a clinical and research affiliate of BUSM.

iPS cells can be developed from adult cell types, such as skin or blood, by returning them to a stem cell state using genetic manipulation. iPS cells are capable of maturing (differentiating) into all the specific cell types in the body, making them a powerful tool for biological research and a source of tissues for transplantation based therapies. Given that iPS cells can be made in a patient-specific manner, there should be great potential for them to be transplanted back into the same patient without rejection. Yet a study published in Nature in 2011 demonstrated that iPS cells transplanted in the stem cell state were rejected in genetically identical recipients.

"The Nature study provocatively suggested that tissues derived from patient-specific iPS cells may be immunogenic after transplantation. However, it never directly assessed the immunogenicity of the therapeutically relevant cell types that could be utilized in regenerative medicine and transplantation," said Rodrigues.

The BUSM researchers evaluated this matter by taking adult cells from an experimental model and deriving iPS cells from them. They then differentiated the iPS cells into three cell types: neuronal (nerve); hepatocytes (liver); and endothelial (blood vessel lining) cells. These three cell types represent each of the three germ layers present during embryonic development -- mesoderm, ectoderm and endoderm. Cells from these layers differentiate and ultimately develop into the body's tissue and organ systems. Using experiments to mirror the potential clinical use of patient-specific iPS cells in cell therapy, the team transplanted each of the differentiated cells into a genetically identical experimental model and found no signs of an elevated immune response or indications of rejection.

The study results suggest that using patient-specific iPS cells should overcome issues of immune rejection in transplantation, which will be a significant problem for potential embryonic stem cell-derived therapies. Immune rejection in transplantation is treated clinically by immunosuppressive drugs but they can have serious side-effects, including the risk of developing cancer.

"If the use of immunosuppressive drugs can be avoided, as may be the case for patient-specific iPS cell based therapies, it would be preferable. Our results are very promising and future work should be directed at assessing whether tissues derived from human iPS cells will similarly lack immunogenicity," said Boyd.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

See the original post:
Potential of differentiated iPS cells in cell therapy without immune rejection

Thelma 9 weeks after Stem Cell Therapy – Video


Thelma 9 weeks after Stem Cell Therapy
I created this video with the YouTube Video Editor (www.youtube.com

By: krazykp12

Read more:
Thelma 9 weeks after Stem Cell Therapy - Video

Thelma 8 weeks after Stem Cell Therapy – Video


Thelma 8 weeks after Stem Cell Therapy

By: krazykp12

Excerpt from:
Thelma 8 weeks after Stem Cell Therapy - Video

Head Injury Improves After Stem Cell Therapy – Video


Head Injury Improves After Stem Cell Therapy
Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

See the article here:
Head Injury Improves After Stem Cell Therapy - Video

Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy – Video


Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy
Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

See the original post here:
Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy - Video

SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic …

MOUNTAIN VIEW, Calif., Jan. 14, 2013 /PRNewswire/ --SanBio Inc. today announced the successful enrollment of the second dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 12 patients, of a planned total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University, the University of Pittsburgh and Northwestern University. No safety concerns have been attributed to the cell therapy product. For details regarding this clinical trial, please refer to http://www.strokeclinicaltrial.org.

SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "The successful completion of the first two dose cohorts of this pioneering clinical trial is a clear indication of the dedication and professionalism of the entire team," said Keita Mori, SanBio CEO.

SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy are also being tested.

"We are pleased with the safety findings of the study thus far," said Dr. Ernest Yankee, SanBio's Executive Vice President of Development. "We anticipate completing the enrollment of the third and final dose cohort early in the year and reporting the results shortly thereafter."

About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: http://www.san-bio.com

The rest is here:
SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic ...

Animal Stem Cell Therapy

St. Bernard Simba's osteoarthritis in his hips, neck and spine has almost immobilized him at just seven years old. Owner, Jennifer McGuire said, "He's extremely painful. He can't get up and down, he can't sit. He can only lay down or stand up, and walking is very painful for him." McGuire is also a technician at the Chattanooga Holistic Animal Institute. They started doing stem cell therapy this week and are the only animal clinic in town doing it. Simba was the first client. "I'm very excited about the technology and very excited about the chance that he may get to live a pain free life," McGuire said. Dr. Colleen Smith says she sees many animals that suffer with arthritis. "Most of your dogs, especially large breed and giant breed dogs I would say almost 89 percent of them have arthritis," said Dr. Smith. She says stem cell therapy is the best treatment out there. "As far as a quality life. That's where I want improvement. I want them to move better and feel better without having the extraneous medicine." Local pet owners got the chance to learn about how the new treatment works. Jason Richardson, National Sales Director of MediVet says it is a one day treatment. "Stem cells are repair cells and it's homing in on inflammation, so we're gonna take these stem cells from the adipose, inject them into these inflammatory environments where these cells can begin to regenerate tissue. So this is one of the first modalities that gets to the root of what's causing the animal's pain," said Richardson. The Chai clinic is already scheduling appointments for pet lovers, and Simba is already starting to feel a little better.

More:
Animal Stem Cell Therapy

Owner hopes stem cell therapy will get dog’s life back

REHOBOTH, Mass. --

A first of its kind procedure is being performed in Massachusetts Monday. Its a stem cell therapy on a dog.

"He can't get comfortable, can't lay down, because of the pain, so he sits up and stares at the wall all night, which is tough to watch," said Bob Cook, Bubbas owner.

Cook of Taunton is talking about his 2-year-old English Bulldog Bubba, who suffers from hip dysplasia.

He said his condition has gotten worse in the last several months. After doing research, he found out about a regenerative stem cell therapy and has been hopeful.

He brought Bubba to the Abbot Animal Hospital in Rehoboth.

"Hopefully we can give these animals relief and increase quality of life and their life span as well, said Dr. Ashraf Gomaa.

Gomaa is the only doctor in our area certified by MediVet America, the company that developed this technology.

After extracting fat from Bubba, it is processed in a machine that basically breaks down the cells to get to the healthy stem cells. The cells are then injected back into Bubba into the area of concern.

"Replacing the bad cells with new cells, pretty advanced technology," Gomaa said.

Read more:
Owner hopes stem cell therapy will get dog's life back

Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost – Video


Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost
stemcellmalaysia.com Stem cell therapy is not a cheap medical treatment. In fact, it is very expensive treatment to the majority of people. The high price of stem cell therapy becomes not only a deterrent to the majority but also creates room for non-medical sector to fill the void of demands for disease treatment. This video addresses the issues surrounding the cost of stem cell therapy, particularly in Malaysia. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.com

By: stemcells2012

Go here to read the rest:
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost - Video

Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.

Centagen has developed a breakthrough stem cell therapy that rejuvenates a patient's own adult stem cells. The Company has found a way to expand a patients own stem cells in the lab millions of times while rejuvenating the cells. For example, a patients blood pleuropotent stem cells could be rejuvenated and expanded in the lab and then re-injected to repair and rejuvenate organs and tissues damaged by aging or disease. Centagen has announced a funding campaign at http://www.indiegogo.com/centagen for additonal research and development.

Boulder, Colorado (PRWEB) December 31, 2012

Each of us has a limited supply of the kind of stem cells needed to rebuild, repair, and rejuvenate any part of our body. As we age, the supply and healing power of our stem cells diminishes. By providing a practically unlimited supply of one's own rejuvenated stem cells, we may keep people young and healthy for well over a century. In particular, regenerating tissues and organs prepared by expanding ones own stem cells could help with Alzheimers disease, diabetes, immune senescence, damaged heart tissue, arteriosclerosis, failing kidneys, failing hearing or eyesight, osteoporosis, weak muscles, and aged skin.

The technology requires no genetic engineering of the stem cells, so the procedure is much safer than the current procedures requiring genetic tampering. Only a patients adult stem cells are used, so there are no ethical issues common with embryonic stem cell use or side effects due to tissue rejection by your immune system.

Centagen has recently opened a crowd funding bid at http://www.indiegogo.com/centagen in concert with Maximum Life foundation, whose mission is to make 100 years old the new 50.

Forward-Looking Statements for Centagen, Inc.

This press release contains several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy of stem cell therapeutics. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company may not update these forward-looking statements in a timely manner as conditions change.

Bryant Villeponteau, Ph.D. Centagen (877) 757-1923 Email Information

Read more:
Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.

New Cerebral Palsy Treatment in India – Video


New Cerebral Palsy Treatment in India
She is a known case of CP with history of full term emergency caesarean section, due to fetal distress and prolong labour, she did not cry at birth and had low APGAR score. She even has history of jaundice on 3rd day of life and was given phototherapy. She was then diagnosed as Hypoxic Ischaemic Encephalopathy. Since then she has been having delayed motor milestones. Neurologically, she is hypertonic and hyperreflexic. On examination:She has poor voluntary control of bilateral lower extremities and fair voluntary control of right upper extremity, but poor voluntary control of left upper extremity; She has no speech developed. She has poor oromotor control and is on semisolid diet. Functionally, she is completely dependent for all ADL and mobility. After Stem Cell Therapy 1. Her drooling has reduced. 2. Tongue lateral movements and elevation initiated. 3. Pursing also initiated. 4. Sucking and chewing initiated. 5. Vocalizations and babbling increased. 6. Blowing initiated. 7. She can stand with minimal support, parallel bar holding from one hand, push knee splint with AFO. Earlier, she had never stood. 8. Her trunk and neck control improved. 9. Her sitting balance and posture is improved. Earlier, she could easily fall to sides with support. Now, she can maintain erect sitting for 5-10 minutes with minimal support. 10. Her left hand opening, weight bearing, grasp and overall usage increased. Now, she reaches to objects. 11. In parallel, with splint on left leg, she can do ...From:neurogenbsiViews:16 1ratingsTime:15:51More inScience Technology

Continue reading here:
New Cerebral Palsy Treatment in India - Video

Stem Cell Therapy Market in Asia Pacific to 2018 Commercialization – Video


Stem Cell Therapy Market in Asia Pacific to 2018 Commercialization
From:Anjali KalanViews:0 0ratingsTime:00:14More inPeople Blogs

See more here:
Stem Cell Therapy Market in Asia Pacific to 2018 Commercialization - Video

PURTIER PRESENTATION – Video


PURTIER PRESENTATION
Please contact Mr.SAMSIUR SAUDJANA @ JAKARTA :+6281699062 Live cell therapy is a very effective stem cell therapy for improving health and even disease treatment other than for beauty and anti-aging.From:SAMSIUR SAUDJANAViews:1 0ratingsTime:09:00More inScience Technology

View post:
PURTIER PRESENTATION - Video

Stem cell therapy procedure – Video


Stem cell therapy procedure
This is a live video of stem cell therapy by intra-arterial procedure to a DMD patient. Muscualr Dystrophy Foundation India has been assisting patients in stem cell therapy in India. Please do visit http://www.mdfindia.orgFrom:MusclecampaignViews:2 0ratingsTime:01:39More inNonprofits Activism

Excerpt from:
Stem cell therapy procedure - Video

Donna Skerrett of Mesoblast on adult stem cell therapies – at Stem Cells USA


Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA RM Congress 2012
Donna Skerrett, Chief Medical Officer of Mesoblast, presented a case study on Mesoblast and their adult stem cell therapy at the Stem Cells USA Regenerative Medicine Congress 2012. The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:30More inScience Technology

Originally posted here:
Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA

Animal Stem Cell Therapy – Video


Animal Stem Cell Therapy
Dr Tim O #39;neill DVM hard at work showing you the amazing results of stem cell and Platlete Rich Plasma treatment.From:Greg SantiniViews:0 0ratingsTime:01:03More inPets Animals

Link:
Animal Stem Cell Therapy - Video

Treatment Plan for Stem Cells Transplantation in Mexico – Part 2 – Video


Treatment Plan for Stem Cells Transplantation in Mexico - Part 2
The video shows a leading stem cell therapist in Mexico discussing in detail the day wise break-up of a treatment plan for stem cell transplantation in Mexico. This is part 2 of the video. This surgeon is one of the pioneers in stem cell research and has cured over 40 patients for otherwise fatal diseases. Over 80% of the patients respond well to the initial treatment he bestows. Despite his track record, the world is still skeptical of stem cell therapies. Many who #39;ve taken a leap of faith by choosing this doctor, found it sufficiently rewarding. The doctor operates from Tijuana, Mexico and you can order a free quote for stem cell transplantation at his Mexico clinic by clicking the link above. Related Searches: stem cell therapy treatment plan mexico, Patient Treatment Plans stem cell Mexico, adult stem cell treatment mexico, autologous stem cell transplant mexico, allogeneic stem cell transplant mexico,From:mexicohealthViews:3 0ratingsTime:01:50More inPeople Blogs

View post:
Treatment Plan for Stem Cells Transplantation in Mexico - Part 2 - Video

Success Rate of Stem Cell Treatments in Mexico – Video


Success Rate of Stem Cell Treatments in Mexico
http://www.mexicohealth.com The video shows a pioneering stem cell surgeon discussing the success rate of stem cell treatments in Mexico. He proclaims more than 80% of his patients show a positive response to the initial therapy. Those who respond well keep returning to his clinic in Tijuana since they start seeing marked improvements in their otherwise irredeemable conditions such as, multiple sclerosis, brain damage, or heart disease. This stem cell specialist from Tijuana has cured over 40 patients for critical illnesses. Claim your FREE quote for stem cell treatments in Mexico by clicking the link above. Related Searches: Successes of Adult Stem Cell Treatments Mexico, success rate for stem cell therapy Mexico, stem cell transplant success rates Mexico, success rate of embryonic stem cells Mexico, Effectiveness of stem cell therapy mexico, stem cell transplant success mexico,From:mexicohealthViews:4 0ratingsTime:01:00More inPeople Blogs

Read the original:
Success Rate of Stem Cell Treatments in Mexico - Video

Treatment Plan for Foreign Patients – Stem Cells Doctor Mexico – Video


Treatment Plan for Foreign Patients - Stem Cells Doctor Mexico
http://www.mexicohealth.com The video shows a top stem cell doctor from Mexico going into the details of treatment plan by breaking it up into day-wise events. The treatment lasts 4-5 days, after which the patients can return to their countries. Tijuana, the doctor #39;s home, is especially appealing to Americans as it offers geographical advantage and low cost stem cell treatments for incurable cases. True that the therapy is far from mainstream, this surgeon #39;s track record of curing over 40 patients is an insight into efficacy of the therapy. He claims more than 80% of the patients respond well to his initial therapy. Get a free quote by stem cells doctor in Mexico by clicking the link above. Related Searches: stem cell therapy treatment plan mexico, Patient Treatment Plans stem cell Mexico, adult stem cell treatment mexico, autologous stem cell transplant mexico, allogeneic stem cell transplant mexico,From:mexicohealthViews:5 0ratingsTime:03:48More inPeople Blogs

Originally posted here:
Treatment Plan for Foreign Patients - Stem Cells Doctor Mexico - Video

What Are Stem Cells – Mexico Specialist – Video


What Are Stem Cells - Mexico Specialist
http://www.mexicohealth.com The video shows a stem cell specialist from Mexico explaining in layman terms the stems cells and how they #39;re harvested. This specialist operates from Tijuana where he has been dedicated to finding a perfect recipe for different life threatening conditions and he has tasted success. With an astonishingly high initial response of over 80%, the doctor has cured over 40 patients for conditions like multiple sclerosis, brain damage, eye problems and cardiac problems. To get a free quote by Mexico specialist in stem cell therapy, click the link above. Related Searches: What are stem cells stem cell definitionFrom:mexicohealthViews:3 0ratingsTime:01:05More inPeople Blogs

Follow this link:
What Are Stem Cells - Mexico Specialist - Video

Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report – Video


Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report
Report provides (www.marketresearchreports.com an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.From:MarketResearchReportViews:0 0ratingsTime:01:21More inScience Technology

Read the original post:
Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report - Video

APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market …

ReportsnReports.com adds Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity to its online market intelligence reports library.

Dallas, Texas (PRWEB) December 21, 2012

The growth in the APAC stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nations economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohns disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to this research and analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals JR-031 in Japan in 2014, and FCB Pharmicells Cerecellgram (CCG) in South Korea in 2015. This research report (http://www.reportsnreports.com/reports/210795-stem-cell-therapy-market-in-asia-pacific-to-2018-commercialization-supported-by-favorable-government-policies-strong-pipeline-and-increased-licensing-activity.html) predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Buy your copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=210795. Alternatively, Request A Sample @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=210795 to help make your purchase decision.

Companies covered in this report include: Stempeutics Research, Reliance Life Sciences, International Stem Cell Services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International (Subsidiary of BioTime, Inc), Stem Cell Technologies I, Pharmicell and Medipost. Equipped with 70 Tables and 60+ Figures, the report Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The research offers market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

Explore more reports on the Stem Cell Market @ http://www.reportsnreports.com/tags/stem-cell-market-research.html.

About Us:

ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Visit link:
APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market ...

Stem cell therapy True or fiction Dr. Ahmed korie alexandria university – Video


Stem cell therapy True or fiction Dr. Ahmed korie alexandria university
Stem cell therapy True or fiction Dr. Ahmed korie alexandria universityFrom:mansvuViews:2 0ratingsTime:29:49More inEducation

Here is the original post:
Stem cell therapy True or fiction Dr. Ahmed korie alexandria university - Video

Stem Cell’s explained part 1 on The Susana Kennedy Show on 2oceansvibe – Video


Stem Cell #39;s explained part 1 on The Susana Kennedy Show on 2oceansvibe
My ever increasing curiosity with the possibilities of Stem Cell therapy recently led me to meeting up with Dr. Duncan Carmichael from The Anti-Aging Clinic in Cape town, we chatted about what stem cell #39;s are, what some of the possibilities are and more, this is part one of a series of interviews I will be releasing over the next few weeks, demystifying the myths and revealing the incredible possibilities that are actually already available to you all right now. Enjoy!From:Susana KennedyViews:2 0ratingsTime:08:32More inScience Technology

Read the original here:
Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe - Video

BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a single clean room for multiple patients, reducing costs and time. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).

Under the terms of the agreement, the companies will develop a commercially viable, safe, reliable, and cost-effective bioreactor for scale-up of BrainStorms NurOwn stem cell therapy, using Octanes Automated Cell & Tissue Engineering System (ACTES) technology. The CIIRDF funding award was approved for a period of three years.

Octane is the ideal partner for us, since they have a particular expertise in developing automated production processes for mesenchymal cell therapy technologies, commented Dr. Adrian Harel, BrainStorms CEO. We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to as many patients as possible, in the near future.

The opportunity to work with BrainStorm on scaling-up the NurOwn production process is a particularly meaningful one, given the urgency of its target population, said Dr. Tim Smith, Octanes CEO. We are confident that our combined knowledge base and commitment to the project will help advance their product significantly closer to clinical use.

BrainStorm is currently conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem and is planning to expand its clinical development in the USA, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

About Octane Biotech

Octane develops innovative bioreactor-based systems to meet the production challenges inherent in the progressive scale-up of manual cell culture protocols. The companys unique Automated Cell & Tissue Engineering System (ACTES) solution integrates state-of-the-art bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech Inc. is one of three affiliated companies within the Octane Medical Group. For more information, visit the companys website at http://www.octaneco.com.

See the original post:
BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

Archives